Table 1 Demographic and baseline characteristics between groups in each Section (n = 30 for each group)
Variables | Section 1 | Section 2 | ||||
|---|---|---|---|---|---|---|
Liraglutide monotherapy | Metformin monotherapy | P | Liraglutide (1.8 mg/d) monotherapy | Liraglutide plus Metformin dual therapy | P | |
Male, n (%) | 16 (53.3) | 17 (46.7) | 0.795 | 16 (53.3) | 17 (46.7) | 0.795 |
Duration of diabetes (year) | 8 ± 5 | 7 ± 4 | 0.396 | 8 ± 5 | 9 ± 6 | 0.486 |
Age at initial visit (year) | 58 ± 15 | 59 ± 17 | 0.810 | 58 ± 16 | 57 ± 14 | 0.798 |
Pre-medication | ||||||
Statins (n) | 2 | 3 | 0.640 | 4 | 4 | 1.000 |
Fibrates (n) | 2 | 1 | 0.554 | 3 | 2 | 0.640 |
ARB (n) | 4 | 3 | 0.688 | 5 | 5 | 1.000 |
ACEI (n) | 1 | 2 | 0.554 | 1 | 0 | 0.313 |
Calcium antagonists (n) | 2 | 2 | 1.000 | 2 | 3 | 0.640 |
Diuretics (n) | 0 | 0 | – | 0 | 1 | 0.313 |
BMI (kg/m2) | 29.56 ± 1.68 | 29.63 ± 1.75 | 0.875 | 29.78 ± 1.85 | 29.66 ± 1.78 | 0.799 |
FPG (mmol/L) HbA1c | 9.3 ± 1.7 | 9.1 ± 2.0 | 0.678 0.749 | 9.0 ± 2.1 | 9.3 ± 1.7 | 0.546 0.758 |
% | 9.0 ± 1.3 | 9.1 ± 1.1 | 9.3 ± 1.3 | 9.4 ± 1.2 | ||
mmol/L | 75 ± 14 | 76 ± 12 | 78 ± 14 | 79 ± 13 | ||
PPG (mmol/L) | 13.8 ± 5.1 | 13.7 ± 4.8 | 0.938 | 13.8 ± 4.9 | 13.6 ± 5.3 | 0.880 |
CRP (mg/L) | 9.5 ± 2.2 | 9.7 ± 2.4 | 0.738 | 9.5 ± 2.2 | 9.7 ± 2.4 | 0.738 |
TG (mmol/L) | 2.8 ± 0.7 | 2.9 ± 0.6 | 0.555 | 2.8 ± 0.6 | 2.9 ± 0.8 | 0.586 |
TC (mmol/L) | 6.2 ± 0.8 | 6.3 ± 0.9 | 0.651 | 6.4 ± 0.8 | 6.3 ± 0.7 | 0.608 |
LDL-C (mmol/L) | 4.1 ± 0.8 | 4.2 ± 0.7 | 0.608 | 4.3 ± 0.8 | 4.2 ± 0.7 | 0.608 |
SBP (mmHg) | 145 ± 9 | 144 ± 8 | 0.651 | 146 ± 7 | 144 ± 8 | 0.307 |
DBP (mmHg) | 92 ± 5 | 93 ± 7 | 0.527 | 94 ± 8 | 93 ± 7 | 0.608 |
LVEDD (mm) | 55 ± 7 | 56 ± 9 | 0.633 | 59 ± 7 | 58 ± 9 | 0.633 |
EF (%) | 48 ± 5 | 47 ± 4 | 0.396 | 46 ± 5 | 47 ± 4 | 0.396 |
E/A ratio | 0.75 ± 0.09 | 0.72 ± 0.07 | 0.155 | 0.73 ± 0.06 | 0.75 ± 0.07 | 0.240 |